The application of the drug for preventing and treating deafness in the preparation of drugs for preventing and treating acute kidney injury caused by cisplatin

Abstract

The application relates to an application of a drug for preventing and treating deafness in preparation of a drug for preventing and treating acute kidney injury caused by cisplatin, wherein the effective component of the drug for preventing and treating acute kidney injury caused by cisplatin is prepared from raw medicinal materials in the following weight percentage: 27-33% of ginseng, 16-20% of astragalus, 16-20% of pueraria, 11-13% of curcuma, 12-15% of platycodon, and 8-10% of licorice. The drug for preventing and treating acute kidney injury caused by cisplatin in the application can obviously reduce the creatinine and urea nitrogen levels, improve the morphological damage of kidney tissues, and has a remarkable effect on preventing and treating acute kidney injury caused by cisplatin.

Description

TECHNICAL FIELD

[0001] The present application relates to medical formulations, in particular to a pharmaceutical preparation containing an unidentified structure from traditional Chinese medicine, which is suitable for preventing and treating acute kidney injury induced by cisplatin. BACKGROUND

[0002] Cisplatin (CDDP) is a platinum-based anticancer drug widely used in the treatment of various types of solid tumors. This drug targets cell DNA and destroys its structural and functional integrity, preventing the proliferation of cancer cells. However, the therapeutic use of cisplatin is accompanied by various side effects, such as nephrotoxicity, neurotoxicity and ototoxicity, limiting its therapeutic application. CDDP is mainly excreted through the kidneys, and the accumulation of its metal platinum ions in the kidneys can cause damage to the kidneys, leading to changes in the function and morphology of glomeruli and renal tubules, and thus triggering significant nephrotoxicity. The toxic effects of CDDP are mainly focused on the renal tubules, causing edema and degeneration of epithelial cells, thickening of the basement membrane, and mild fibrosis in the renal interstitium. These changes ultimately lead to apoptosis and necrosis of renal tubular epithelial cells, forming transparent cast structures, accompanied by an increase in serum urea nitrogen (BUN) and serum creatinine (SCr) levels, further confirming the damage to kidney function (Chen Y. Research Progress on the Protective Effect of Traditional Chinese Medicine Components on Cisplatin Nephrotoxicity and Its Mechanism [J]. Oncology Pharmacy, 2020, 10(01): 21-26.).

[0003] The main measures for clinical treatment of acute kidney injury induced by cisplatin at present include, for example, adequate hydration before and after the use of cisplatin to dilute the drug concentration in the urine and reduce the damage to the kidneys. At the same time, doctors may adjust the drug dosage according to the patient's renal function, regularly monitor renal function indicators, and avoid the use of other drugs that may exacerbate kidney burden. The main drugs used in clinical practice for cisplatin-induced kidney injury are mannitol, amifostine and tranexamic acid, etc., but they have low efficiency, poor patient compliance, and are prone to cause adverse reactions such as electrolyte imbalance, so the research and development of drugs for the treatment of cisplatin-induced kidney injury is a continuous challenge and urgent need.

[0004] Traditional Chinese medicine has recorded acute kidney injury very early. According to its onset, sudden decrease in urine volume, and edema of limbs, it is classified into the categories of urinary retention, dousing poison, and obstruction. The spleen and kidney are damaged, the spleen is responsible for transportation and transformation, the kidney is responsible for water and sealing, and it plays an important role in the body's water metabolism and the function of zang-fu organs. Drug poison belongs to turbid evil, which accumulates in the spleen and kidney. On the one hand, it damages the spleen and the kidney, and the function is abnormal, the sealing is out of control, the body fluid is not transported, and it is not able to guide the evil out, so that the turbid evil stays; on the other hand, the drug poison is contained, the qi movement is blocked, and pathological products such as phlegm and blood stasis are produced. If it is not removed for a long time, it will become a pathogenic factor, damage the spleen and kidney, cause the vicious cycle of deficiency of the healthy and overabundance of the evil, and cause the disease. Therefore, the principle of strengthening the body resistance and eliminating evil is adopted, the methods of invigorating the spleen and tonifying qi, promoting blood circulation and removing blood stasis, and promoting water and removing toxin are used to prevent and treat acute kidney injury caused by cisplatin (Teng Zhiying. Research on the effect and possible mechanism of Qiongyu Gao in reducing cisplatin nephrotoxicity[D]. Nanjing University of Chinese Medicine, 2015.)

[0005] The patent application with the publication number CN 117180386A discloses a drug for preventing and treating drug-induced deafness and presbycusis, and the effective components are made of raw medicinal materials in the following weight percentages: 9-13% of ginseng, 31-35% of astragalus, 9-13% of turmeric, 20-24% of pueraria, 9-13% of platycodon, and 9-13% of licorice. Meanwhile, the patent application also discloses the following contents: ginseng and astragalus are the monarch, the former can greatly supplement the qi of five zang organs, especially the spleen and the lung, and the latter can tonify qi and raise yang, and the combination of the two can greatly supplement the primordial qi, make the clear qi ascend and nourish the ears; turmeric and pueraria are the ministers, the former can activate blood and promote qi circulation, and the latter can activate collaterals and assist the monarch in ascending and promoting the clear yang and unblocking the ears; platycodon is the assistant, which can open and promote the lung qi, clear the head and eyes, and carry the medicine upward; and licorice is the guide, which can tonify the spleen and lung, clear heat and remove toxin, and harmonize various drugs. The combination of the drugs can supplement the spleen and lung, ascend the clear qi, remove blood stasis, unblock the orifices, and restore hearing. However, drug-induced deafness and presbycusis are two different diseases from the acute kidney injury caused by cisplatin, and the pathogenesis and clinical symptoms are completely different, so the ordinary skilled in the art cannot infer that the drug described in the patent application can be transformed into a therapeutic use for preventing and treating acute kidney injury. SUMMARY

[0006] The technical problem to be solved by the present application is to provide a new use of a drug for preventing and treating deafness, i.e. a new application in pharmacy.

[0007] The new use of the drug for preventing and treating deafness is:

[0008] The application of the drug for preventing and treating drug-induced deafness and presbycusis in the preparation of a drug for preventing and treating acute kidney injury caused by cisplatin, wherein the effective components of the drug for preventing and treating acute kidney injury caused by cisplatin are made of raw medicinal materials in the following weight percentages:

[0009] Radix ginseng 27-33%, Radix astragali 16-20%, Radix puerariae 16-20%, Curcuma longa 11-13%, Platycodon grandiflorum 12-15%, Glycyrrhiza 8-10%.

[0010] In the above application, the six Chinese medicinal ingredients used in the drug for preventing and treating drug-induced deafness and presbycusis are the same as those in the patent application with the authorization announcement number CN 117180386B.

[0011] In the application, the optimal proportion of the raw medicinal ingredients is as follows:

[0012] Radix ginseng 29.9%, Radix astragali 17.9%, Radix puerariae 17.9%, Curcuma longa 11.9%, Platycodon grandiflorum 13.4%, and Glycyrrhiza 9.0%.

[0013] In the application, the effective component is prepared by the following method:

[0014] (1) The raw medicinal ingredients are placed in a traditional Chinese medicinal decocting pot, 8-12 times of water is added for soaking for 1-2 hours, and then boiled with a strong fire and slowly boiled with a weak fire for 1-2 hours, followed by filtration to collect the first decoction;

[0015] (2) The residue is added with 6-10 times of water, boiled with a strong fire and slowly boiled with a weak fire for 40-60 minutes, followed by filtration to collect the second decoction;

[0016] (3) The two decoctions are combined, concentrated by evaporation to a concentrated solution with a concentration of 1g crude drug / mL, and dried to obtain the effective component.

[0017] In the application, the drug for preventing and treating acute kidney injury caused by cisplatin is a conventional granule, tablet, capsule or oral liquid.

[0018] In the composition of the drug for preventing and treating acute kidney injury caused by cisplatin, Radix ginseng is the monarch drug for tonifying primordial qi, generating fluid to relieve thirst, benefiting kidney qi and assisting kidney yang; Radix astragali is the ministerial drug for tonifying qi to raise yang, benefiting defense to consolidate the exterior, benefiting water to reduce swelling and assisting Radix ginseng to tonify primordial qi; Radix puerariae is the ministerial drug for relieving the exterior and reducing fever and generating fluid to relieve thirst; Curcuma longa and Platycodon grandiflorum are the adjuvants, Curcuma longa promotes blood circulation to remove blood stasis and dredge collaterals, and Platycodon grandiflorum expels internal evils by eliminating phlegm and diuresis; Glycyrrhiza is the controller for tonifying the spleen and benefiting qi, clearing heat and detoxifying, and harmonizing all drugs. The combination of the drugs can tonify the spleen and kidney, promote blood circulation to dredge collaterals, benefit water to detoxify and generate fluid to relieve thirst. The drug in the application can significantly reduce the levels of creatinine and urea nitrogen, improve the morphological damage of kidney tissue, and has a remarkable effect on preventing and treating acute kidney injury caused by cisplatin.

[0019] The drug for preventing and treating acute kidney injury caused by cisplatin in the present application is converted from the composition of the invention patent application with publication number CN 117180386A, and the specific conversion method is: from the aspect of medicinal ingredient ratio, increasing the proportion of ginseng, radix puerariae, turmeric and platycodon grandiflorum in the prescription, and reducing the proportion of radix astragali and licorice in the prescription; from the aspect of prescription structure, reusing ginseng as the monarch with its single flavor, reducing radix astragali to the minister and combining with radix puerariae as the minister, and reducing turmeric to the adjuvant and combining with platycodon grandiflorum as the adjuvant. The above improvements can produce the following beneficial effects: 1. Ginseng is distributed in the spleen, lung, heart and kidney channels, and can greatly supplement the qi of five zang organs, and is a drug for supporting the healthy and expelling the evil, which can better supplement kidney qi and assist kidney yang; 2. Radix astragali can benefit water and dissipate swelling, and radix puerariae can generate fluid and stop thirst, and the combination of the two can effectively promote the excretion of urine and the excretion of toxins in the body, reduce the burden on the kidney, and play an important role in the recovery of acute kidney injury; 3. Turmeric is distributed in the spleen, stomach and liver channels, and can activate blood and regulate qi, resolve stasis and dredge collaterals, and platycodon grandiflorum is distributed in the lung channel, and can dredge the upper jiao and lead the drug upward, and the combination of the two can jointly regulate qi movement and ensure the smoothness of lung and kidney qi movement, which is helpful for the harmonious operation of blood and qi in the whole body, so that the drug effect can better reach the kidney.

[0020] From the above analysis, it can be seen that the treatment method of the drug for preventing and treating acute kidney injury caused by cisplatin in the present application is changed from the original “tonifying the spleen and lung” to “tonifying the qi of the spleen and kidney and benefiting water and resolving toxins”, which greatly enhances the effect of “tonifying kidney qi” and can significantly improve the effect of preventing and treating acute injury caused by cisplatin. Aminoglycoside drugs also belong to turbid evil and are easy to accumulate in the spleen and kidney, and at the same time, they can disturb the qi movement, so that the turbid evil remains in the body and damages the kidney, causing acute kidney injury. Therefore, the drug for preventing and treating deafness can also be used for acute kidney injury caused by aminoglycoside drugs.

[0021] In order to better understand the beneficial effects of the present application, the following will be further illustrated through examples and animal experiments. DETAILED DESCRIPTION

[0022] 1. Experimental materials

[0023] 1.1 Experimental animals: SPF level male ICR mice (25-30g) were purchased from Guangdong Medical Experimental Animal Center, and after passing the quality inspection of Guangdong Medical Experimental Animal Center, they were allowed to enter the experimental animal center of Guangdong Pharmaceutical University for feeding. The feeding temperature was controlled at 20-25℃, the humidity was 40%-60%, the light and dark alternated for 12h, the water was changed in time according to the regulations, and the litter was replaced, the experimental strictly abided by the relevant regulations of national and Guangdong animal welfare ethics and protection, and the animal experiment number was SPF2022379.

[0024] 1.2 Experimental Materials: Cisplatin injection, purchased from Qilu Pharmaceutical Co., Ltd.; 1% normal saline, purchased from Jinkelong Biotechnology Co., Ltd.; pentobarbital, purchased from Chengdu Grecia Chemical Technology Co., Ltd.; amifostine for injection, purchased from Merro Pharmaceutical Co., Ltd.; paraformaldehyde, purchased from Shanghai MacLean Biochemical Technology Co., Ltd.; blood urea nitrogen test kit and creatinine determination kit, purchased from Nanjing Jiancheng Bioengineering Institute.

[0025] 1.3 Experimental instruments: Intelligent cell imaging system, Thermo Fisher Scientific Inc.; Multifunctional microwell reader, Thermo Fisher Scientific Inc.

[0026] 2 Experimental methods

[0027] 2.1 Solution preparation

[0028] 1% pentobarbital solution: Accurately weigh 1 g of pentobarbital, dissolve it in appropriate amount of distilled water, and then dilute to volume in a 100 mL volumetric flask.

[0029] 4% paraformaldehyde solution: Accurately weigh 10 g of paraformaldehyde and place it in a beaker. Add 250 mL of PBS and heat at 55°C with stirring. After dissolving, cool to room temperature and dilute to volume in a 250 mL volumetric flask.

[0030] Test drug of experimental group 1: The granules of Example 1 were prepared by adding 1% normal saline to prepare a test drug of 3 g crude drug / mL.

[0031] Test drug of experimental group 2: The granules of Example 2 were taken and 1% normal saline was added to prepare the test drug at a concentration of 3 g crude drug / mL.

[0032] Test drug of experimental group 3: The granules of Example 3 were taken and 1% normal saline was added to prepare the test drug at a concentration of 3 g crude drug / mL.

[0033] The test drug for the positive control group was: Amifostine for injection was added with 1% normal saline to prepare a test drug concentration of 0.03 mg / mL.

[0034] The test drug of the control group: the granules of Example 1 of the patent application with publication number CN 117180386A, to which 1% normal saline was added to prepare 3 g crude drug / mL of the test drug.

[0035] 2.2 Efficacy of the test drugs on cisplatin-induced acute kidney injury

[0036] (1) Grouping and administration: 42 male ICR mice were randomly divided into blank control group, model group, positive control group, control group and experimental groups 1-3, a total of 7 groups. The blank control group and the model group were given corresponding volume of normal saline by gavage, for 14 days; the positive control group: intraperitoneal injection of amifostine at a dose of 2 mg / kg, for 14 days; the control group: the control group drug solution was given by gavage at a dose of 9g crude drug / kg, for 14 days; experimental group 1: the experimental group 1 drug solution was given by gavage at a dose of 9g crude drug / kg, for 14 days; experimental group 2: the experimental group 2 drug solution was given by gavage at a dose of 9g crude drug / kg, for 14 days; experimental group 3: the experimental group 3 drug solution was given by gavage at a dose of 9g crude drug / kg, for 14 days. On the 15th day, except for the blank control group, the rest of the groups were given cisplatin solution at a dose of 25mg / kg by intraperitoneal injection for modeling; 72 hours later, the mice in each group were anesthetized with 1% pentobarbital, blood was collected by removing the eyeball into a heparin sodium treated blood collection tube, centrifuged at 3000 rpm for 10 min, and the plasma was prepared for use; the double kidney tissues were weighed and stored in 4% paraformaldehyde.

[0037] (2) Detection of related indicators: the kidney coefficient of each group of mice was calculated (kidney coefficient = double kidney tissue weight / mouse body weight x 100%); the plasma samples of each group of mice were detected according to the instructions of the blood creatinine (CRE) and urea nitrogen (BUN) kit to detect the content of creatinine and urea nitrogen in the serum of each group of mice; the kidney tissues of each group of mice were sent to the company for HE staining observation.

[0038] 2.3 Statistical method

[0039] The results were expressed as mean ± standard deviation (Mean ± SD), and analyzed by GraphPad Prism 5 statistical software, and the differences between groups were compared by one-way ANOVA. P<0.05 indicates that the difference is statistically significant.

[0040] 3 Results and discussion

[0041] 3.1 Effect of test drug on kidney coefficient of cisplatin-induced acute kidney injury mice

[0042] The experimental results are shown in Table 1. Compared with the model group, the kidney coefficient of the blank control group was significantly increased (P<0.001). Compared with the model group, the kidney coefficient of the positive control group, the control group, experimental group 1, experimental group 2 and experimental group 3 was significantly decreased (P<0.001, P<0.01, P<0.05). Compared with the positive control group, the kidney coefficient of experimental groups 1-3 had no significant difference (P>0.05). Compared with the control group, the kidney coefficient of experimental groups 1-3 was significantly better than that of the control group (P<0.05). The above results show that cisplatin induction can significantly cause acute kidney injury. The control group and experimental groups 1-3 can alleviate the edema or congestion caused by cisplatin. The effect of experimental group 1 (the best ratio) is the best, and the effect is significantly better than that of the control group.

[0043] Table 1: Kidney coefficient of each group of animals (n=6)

[0044] Group Organ coefficient (%) Control group 1.70 ± 0.11 *** ]] Model group 2.62±0.14 Positive control group 1.98 ± 0.37 ** ]] Control group 2.28 ± 0.15 * ]] Experimental group 1 1.80 ± 0.28 ***#ns ]] Experimental group 2 1.88 ± 0.56 ***#ns ]] Experimental group 3 1.91 ± 0.25 ***#ns ]]

[0045] Note: Compared with the control group # P<0.05, ***P<0.001, **P<0.01, *P<0.05, compared with the model group; ns P>0.05, compared with the positive control group.

[0046] 3.2 Effect of the test drug on the kidney function of mice with cisplatin-induced acute kidney injury

[0047] The experimental results are shown in Table 2. Compared with the model group, the creatinine and urea nitrogen content of the blank control group was significantly increased (P<0.001). Compared with the model group, the creatinine and urea nitrogen content of the positive control group, the control group, experimental groups 1-3 was significantly decreased (P<0.001, P<0.01). Compared with the positive control group, experimental groups 1-3 had no significant difference (P>0.05). Compared with the control group, the creatinine and urea nitrogen level of experimental groups 1-3 was significantly lower than that of the control group (P<0.001, P<0.05). The above results show that cisplatin induction can significantly increase the content of creatinine and urea nitrogen in plasma. The control group and experimental groups 1-3 can alleviate the increase of creatinine and urea nitrogen content caused by cisplatin. The effect of experimental group 1 (the best ratio) is the best, and the effect is better than that of the control group.

[0048] Table 2: Creatinine and urea nitrogen content in plasma samples of each group of animals (n=6)

[0049] Group Creatinine (μmol / L) Urea nitrogen (μmol / L) Control group 36.69 ± 10.90 *** ]] 3.95 ± 0.56 *** ]] Model group 187.13±38.27 16.03±1.59 Positive control group 100.84 ± 29.31 *** ]] 8.16 ± 1.92 *** ]] Control group 149.99 ± 6.69 ** ]] 10.35 ± 0.71 *** ]] Experimental group 1 95.04 ± 29.99 ***###ns ]] 7.10 ± 1.10 ***###ns ]] Experimental group 2 120.95.16 ± 29.99 ***#ns ]] 8.36 ± 1.94 ***#ns ]] Experimental group 3 122.28 ± 8.83 ***#ns ]] 8.59 ± 1.27 ***#ns ]]

[0050] Note: Compared with the control group # P<0.05, ### P<0.001, compared with the model group ***P <0.001, ** P<0.01, compared with the positive control group nsP>0.05.

[0051] 3.3 Effect of the test drug on the renal tissue morphology of mice with cisplatin-induced acute kidney injury

[0052] The experimental results are shown in Table 1. Figure 1 As shown in Table 1, the kidney tissue structure of the blank control group was complete, the renal tubules were not dilated or atrophic, and there was no inflammatory cell infiltration. The kidney tissue structure of the model group was severely abnormal, the renal tubules were widely degenerated, the renal tubular epithelial cells were atrophic, the lumen was dilated, and protein casts were visible, and the lumen was filled with protein mucus; the renal tubular epithelial cells were vacuolated, the cell outline was not clear, and the cytoplasm was loose and vacuolated; a small amount of inflammatory cells infiltrated the tissue. The kidney tissue injury of the positive control group and each drug administration group was significantly reduced, and the specific performance was that the kidney tissue structure was arranged in order, the degree of necrosis of the renal tubular epithelial cells was reduced, and the degree of pathological injury of the kidney tissue of the experimental groups 1-3 was lower than that of the control group. The above results show that the control group and the experimental groups 1-3 can effectively alleviate cisplatin-induced acute kidney injury.

[0053] 3.4 Conclusion

[0054] After the mice treated by the drug of the present application were injected with cisplatin, the edema or hyperemia of the kidney was significantly inhibited, and the increase of the contents of creatinine and urea nitrogen was inhibited, which had a significant protective effect on kidney injury. The drug of the present application can be used to prepare a drug for preventing and treating cisplatin-induced acute kidney injury. BRIEF DESCRIPTION OF DRAWINGS

[0055] Figure 1 Figure 1 is a micrograph (200x field) of HE staining of the kidney tissue of each group of mice. DETAILED DESCRIPTION

[0057] Example 1 (granules)

[0058] 1. Prescription:

[0059] Ginseng 200g, Astragalus 120g, Pueraria 120g, Turmeric 80g, Platycodon 90g, Licorice 60g.

[0060] 2. Preparation method:

[0061] (1) Precisely weigh the above-mentioned raw materials and place them in a traditional Chinese medicine pot. Soak in 11 times water for 1.5h, then boil with a strong fire and slowly simmer with a weak fire for 1.5h, then filter and collect the first decoction.

[0062] (2) Add 8 times water to the residue, boil with a strong fire, then slowly simmer with a weak fire for 50min, filter and collect the second decoction.

[0063] (3) Combine the two decoctions, evaporate and concentrate to 1 g crude drug / mL of concentrated solution, dry, then add appropriate amount of sucrose and dextrin to 300 g, add appropriate amount of water to make granules, then dry, size, and pack into 15 g / pack.

[0064] Example 2 (granules)

[0065] 1. Prescription:

[0066] Radix ginseng 180 g, Radix astragali 126 g, Radix puerariae 132 g, Curcuma longa 86 g, Platycodon grandiflorum 86 g, Radix glycyrrhizae 60 g.

[0067] 2. Preparation method:

[0068] (1) Precisely weigh the above raw materials and place them in a traditional Chinese medicine pot, add 8 times water, soak for 2 h, then boil with strong fire and slowly boil with weak fire for 1 h, then filter and collect the first decoction.

[0069] (2) Add 6 times water to the residue, boil with strong fire, then slowly boil with weak fire for 40 min, filter and collect the second decoction.

[0070] (3) Combine the two decoctions, evaporate and concentrate to 1 g crude drug / mL of concentrated solution, dry, then add appropriate amount of sucrose and dextrin to 300 g, add appropriate amount of water to make granules, then dry, size, and pack into 15 g / pack.

[0071] Example 3 (granules)

[0072] 1. Prescription:

[0073] Radix ginseng 215 g, Radix astragali 125 g, Radix puerariae 118 g, Curcuma longa 72 g, Platycodon grandiflorum 81 g, Radix glycyrrhizae 59 g.

[0074] 2. Preparation method:

[0075] (1) Precisely weigh the above raw materials and place them in a traditional Chinese medicine pot, add 12 times water, soak for 1 h, then boil with strong fire and slowly boil with weak fire for 2 h, then filter and collect the first decoction.

[0076] (2) Add 10 times water to the residue, boil with strong fire, then slowly boil with weak fire for 60 min, filter and collect the second decoction.

[0077] (3) Combine the two decoctions, evaporate and concentrate to 1 g crude drug / mL of concentrated solution, dry, then add appropriate amount of sucrose and dextrin to 300 g, add appropriate amount of water to make granules, then dry, size, and pack into 15 g / pack.

[0078] Example 4 (capsules)

[0079] The drug granules prepared according to the method of Example 1 are filled into empty capsules, 0.8 g per capsule, to prepare capsules.

[0080] Example 5 (tablets)

[0081] The drug granules prepared according to the method of Example 1 are tabletted, coated, to prepare tablets, with a tablet core weight of 0.8 g.

[0082] Example 6 (oral liquid)

[0083] 1. Prescription:

[0084] Radix ginseng 200 g, Radix astragali 120 g, Radix puerariae 120 g, Curcuma longa 80 g, Platycodonis 90 g, Radix glycyrrhizae 60 g.

[0085] 2. Preparation method:

[0086] (1) The above raw materials are precisely weighed and placed in a traditional Chinese medicine pot, 12 times the amount of water is added and soaked for 1 h, then boiled with a strong fire and slowly boiled with a weak fire for 1 h, then filtered and collected the first decoction.

[0087] (2) The residue is added with 10 times the amount of water, boiled with a strong fire, then slowly boiled with a weak fire for 40 min, filtered and collected the second decoction.

[0088] (3) The two decoctions are combined, evaporated and concentrated to a concentrated solution of 1 g of crude drug / mL, 0.03% xanthan gum, 0.1% pectin and 0.1% soluble soybean polysaccharide are selected according to the volume percentage, mixed and swelled, then heated and dissolved, mixed with the concentrated solution, added with 0.1% mogroside, 0.05% citric acid and 0.05% salt, canned, sterilized, and obtained, with a specification of 70 mL per bottle.

Claims

1. The use of a drug for preventing and treating drug-induced deafness and presbycusis in the preparation of a drug for preventing and treating acute kidney injury caused by cisplatin, wherein the effective component of the drug for preventing and treating acute kidney injury caused by cisplatin is prepared from raw medicinal materials in the following weight percentages: 27-33% of ginseng, 16-20% of astragalus, 16-20% of pueraria, 11-13% of curcuma, 12-15% of platycodon, and 8-10% of licorice. The effective component is prepared from raw medicinal materials in the following weight percentages: 29.9% of ginseng, 17.9% of astragalus, 17.9% of pueraria, 11.9% of curcuma, 13.4% of platycodon, and 9.0% of licorice.

2. Use according to claim 1, characterized in that, The effective component is prepared by the following method: (1) The raw medicinal materials are placed in a traditional Chinese medicine pot, 8-12 times of water is added for soaking for 1-2 hours, and then boiled with a strong fire and slowly boiled with a weak fire for 1-2 hours, and then filtered to collect the first decoction; 3. Use according to claim 1 or 2, characterized in that, (2) The residue is added with 6-10 times of water, boiled with a strong fire, and then slowly boiled with a weak fire for 40-60 minutes, and then filtered to collect the second decoction; (3) The two decoctions are combined, concentrated to a concentrated solution of 1g of crude drug per mL, and then dried to obtain the effective component. The drug for preventing and treating acute kidney injury caused by cisplatin is in the form of granules, tablets, capsules, or oral liquid. ​ 4. Use according to claim 3, characterized in that, ​

Images